Spero Therapeutics, Inc.SPRONASDAQ
LOADING
|||
Gross Profit Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year gross profit growth rate
Latest
-74.17%
↑ 77% above average
Average (36q)
-319.34%
Historical baseline
Range
High:4184.10%
Low:-12947.67%
Volatility
-5364.8%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | -74.17% |
| Q2 2025 | 252.64% |
| Q1 2025 | 90.29% |
| Q4 2024 | -690.91% |
| Q3 2024 | 199.56% |
| Q2 2024 | -421.79% |
| Q1 2024 | -82.55% |
| Q4 2023 | -3.08% |
| Q3 2023 | 465.82% |
| Q2 2023 | 1.68% |
| Q1 2023 | -114.91% |
| Q4 2022 | 4184.10% |
| Q3 2022 | 20.76% |
| Q2 2022 | 262.75% |
| Q1 2022 | 101.71% |
| Q4 2021 | -2145.34% |
| Q3 2021 | -66.38% |
| Q2 2021 | 118.97% |
| Q1 2021 | -682.28% |
| Q4 2020 | 113.91% |
| Q3 2020 | -893.92% |
| Q2 2020 | 109.22% |
| Q1 2020 | 15.22% |
| Q4 2019 | -12947.67% |
| Q3 2019 | -92.02% |
| Q2 2019 | -43.37% |
| Q1 2019 | 125.00% |
| Q4 2018 | 157.14% |
| Q3 2018 | 42.12% |
| Q2 2018 | -59.84% |
| Q1 2018 | 16.11% |
| Q4 2017 | 66.33% |
| Q3 2017 | 139.76% |
| Q2 2017 | 77.86% |
| Q1 2017 | -58.21% |
| Q4 2016 | 0.00% |
| Q3 2016 | 0.00% |